DUL:ETR
Alnylam Pharmaceuticals, Inc.
205,50 €
arrow_downward
-0,48%(-1,00) 1K
12-okt, 17:35:58 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoDUL tikeri uchun statistika yaratilmoqda...
Ochish
209,10 €
Yuqori
209,10 €
Past
205,50 €
Bozor kapitali
30,38Â mlrd
Oʻrtacha hajm
40,00
Hajmi
10,00
52 haftalik eng yuqori
417,40 €
52 haftalik eng past
177,10 €
Xodimlar soni
2Â ming
Ochish
209,10 €
Yuqori
209,10 €
Past
205,50 €
Bozor kapitali
30,38Â mlrd
Oʻrtacha hajm
40,00
Hajmi
10,00
52 haftalik eng yuqori
417,40 €
52 haftalik eng past
177,10 €
Xodimlar soni
2Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Investing.com
·
1 kun oldin
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
1 kun oldin
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
1 kun oldin
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Yahoo Finance
·
2 kun oldin
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Alnylam Pharmaceuticals, Inc. haqida